(CercleFinance.com) – AstraZeneca announced on Thursday that its cancer tablet Lynparza will receive priority review in the United States for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Lynparza, developed in partnership with the American Merck, targets tumors with a certain deficit with the aim of killing cancer cells selectively.
The FDA’s decision, which concerns the combination of the drug with abiraterone and prednisone or prednisolone alone, is based on phase III data which showed that this type of combination reduced the risk of death or death by 34%. disease progression in treated patients.
Final FDA clearance is expected in the fourth quarter.
Lynparza is already approved in several countries to treat a number of cancers, such as breast cancer, ovarian cancer or pancreatic cancer.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
